Literature DB >> 20220779

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.

A Pellagatti1, M Cazzola, A Giagounidis, J Perry, L Malcovati, M G Della Porta, M Jädersten, S Killick, A Verma, C J Norbury, E Hellström-Lindberg, J S Wainscoat, J Boultwood.   

Abstract

To gain insight into the molecular pathogenesis of the myelodysplastic syndromes (MDS), we performed global gene expression profiling and pathway analysis on the hematopoietic stem cells (HSC) of 183 MDS patients as compared with the HSC of 17 healthy controls. The most significantly deregulated pathways in MDS include interferon signaling, thrombopoietin signaling and the Wnt pathways. Among the most significantly deregulated gene pathways in early MDS are immunodeficiency, apoptosis and chemokine signaling, whereas advanced MDS is characterized by deregulation of DNA damage response and checkpoint pathways. We have identified distinct gene expression profiles and deregulated gene pathways in patients with del(5q), trisomy 8 or -7/del(7q). Patients with trisomy 8 are characterized by deregulation of pathways involved in the immune response, patients with -7/del(7q) by pathways involved in cell survival, whereas patients with del(5q) show deregulation of integrin signaling and cell cycle regulation pathways. This is the first study to determine deregulated gene pathways and ontology groups in the HSC of a large group of MDS patients. The deregulated pathways identified are likely to be critical to the MDS HSC phenotype and give new insights into the molecular pathogenesis of this disorder, thereby providing new targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20220779     DOI: 10.1038/leu.2010.31

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  120 in total

Review 1.  Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Alexander Scarth Watson; Monika Mortensen; Anna Katharina Simon
Journal:  Cell Cycle       Date:  2011-06-01       Impact factor: 4.534

2.  The 5q- syndrome: biology and treatment.

Authors:  Eric Padron; Rami Komrokji; Alan F List
Journal:  Curr Treat Options Oncol       Date:  2011-12

3.  Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.

Authors:  Laura Barreyro; Britta Will; Boris Bartholdy; Li Zhou; Tihomira I Todorova; Robert F Stanley; Susana Ben-Neriah; Cristina Montagna; Samir Parekh; Andrea Pellagatti; Jacqueline Boultwood; Elisabeth Paietta; Rhett P Ketterling; Larry Cripe; Hugo F Fernandez; Peter L Greenberg; Martin S Tallman; Christian Steidl; Constantine S Mitsiades; Amit Verma; Ulrich Steidl
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

4.  Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.

Authors:  Raphael Ceccaldi; Delphine Briot; Jérôme Larghero; Nadia Vasquez; Catherine Dubois d'Enghien; Delphine Chamousset; Maria-Elena Noguera; Quinten Waisfisz; Olivier Hermine; Corinne Pondarre; Thierry Leblanc; Eliane Gluckman; Hans Joenje; Dominique Stoppa-Lyonnet; Gérard Socié; Jean Soulier
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

Review 5.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

6.  Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.

Authors:  N Hasegawa; M Oshima; G Sashida; H Matsui; S Koide; A Saraya; C Wang; T Muto; K Takane; A Kaneda; K Shimoda; C Nakaseko; K Yokote; A Iwama
Journal:  Leukemia       Date:  2016-10-03       Impact factor: 11.528

7.  SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.

Authors:  Jie Sun; Xin He; Yinghui Zhu; Zonghui Ding; Haojie Dong; Yimei Feng; Juan Du; Hanying Wang; Xiwei Wu; Lei Zhang; Xiaochun Yu; Allen Lin; Tinisha McDonald; Dandan Zhao; Herman Wu; Wei-Kai Hua; Bin Zhang; Lifeng Feng; Kaoru Tohyama; Ravi Bhatia; Philipp Oberdoerffer; Yang Jo Chung; Peter D Aplan; Jacqueline Boultwood; Andrea Pellagatti; Samer Khaled; Marcin Kortylewski; Flavia Pichiorri; Ya-Huei Kuo; Nadia Carlesso; Guido Marcucci; Hongchuan Jin; Ling Li
Journal:  Cell Stem Cell       Date:  2018-08-23       Impact factor: 24.633

8.  Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells.

Authors:  Y Wei; R Chen; S Dimicoli; C Bueso-Ramos; D Neuberg; S Pierce; H Wang; H Yang; Y Jia; H Zheng; Z Fang; M Nguyen; I Ganan-Gomez; B Ebert; R Levine; H Kantarjian; G Garcia-Manero
Journal:  Leukemia       Date:  2013-03-29       Impact factor: 11.528

9.  Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Authors:  Véronique Gelsi-Boyer; Nathalie Cervera; François Bertucci; Mandy Brecqueville; Pascal Finetti; Anne Murati; Christine Arnoulet; Marie-Joelle Mozziconacci; Ken I Mills; Nicholas C P Cross; Norbert Vey; Daniel Birnbaum
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

10.  Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes.

Authors:  Sriram Sundaravel; Ryan Duggan; Tushar Bhagat; David L Ebenezer; Hui Liu; Yiting Yu; Matthias Bartenstein; Madhu Unnikrishnan; Subhradip Karmakar; Ting-Chun Liu; Ingrid Torregroza; Thomas Quenon; John Anastasi; Kathy L McGraw; Andrea Pellagatti; Jacqueline Boultwood; Vijay Yajnik; Andrew Artz; Michelle M Le Beau; Ulrich Steidl; Alan F List; Todd Evans; Amit Verma; Amittha Wickrema
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.